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Summary Tissue specimens from 150 patients with localised prostatic carcinomas and 116 patients with
prostatic carcinomas with distant metastases were analysed for histological grade (WHO and Gleason) and
immunoreactivity for prostate acid phosphatase (PAP), prostate-specific antigen (PSA), neurone-specific
enolase (NSE), p53 protein, c-erbB-2 protein, cytokeratins (AEI/AE3) and vimentin. After stratification for
the presence or absence of distant metastases, multivariate regression analysis revealed that WHO grading was
the most powerful independent prognosticator, followed by age and prostate acid phosphatase expression.
There was a trend towards reduced survival with decreasing prostate-specific antigen reactivity. The Gleason
system showed poor prognostic ability. The analysis predicted reduced survival in the presence of extensive
neurone-specific enolase reactivity, mostly because of one case of small-cell carcinoma.
Prostate cancer exhibits great variation in biological
behaviour (Gleason et al., 1974; Murphy et al., 1982; Epstein
et al., 1986; Johansson et al., 1989; Smith et al., 1991;
Whitmore et al., 1991). Any parameter that reflects the
malignant potential of an individual tumour may be of
decisive importance for the clinician. Histological grade and
extension of the disease are at present the discriminating
prognosticators most frequently used.
In recent years, several additional biological tumour
markers have been presented. Immunohistochemical demons-
tration of neuroendocrine features (di Sant'Agnese & de
Mesy Jensen, 1987; Cohen et al., 1991), c-erbB-2 protein
(Gullick et al., 1991; Reilly et al., 1991; Hale et al., 1992),
p53 protein (Porter et al., 1992), prostate acid phosphatase
(PAP) (Sakai et al., 1991), prostate-specific antigen (PSA)
(Hammond et al., 1989; Bazinet et al., 1992) and vimentin
(Leong et al., 1988) has been related to tumour prognosis.
However, at present there is no general agreement concerning
the best combination of prognostic factors.
The aim of this study was to examine the prognostic
significance of each of the above-mentioned factors in tissue
sections (histological grade, cellular atypia, PSA, PAP, c-
erbB-2 protein, p53 protein, vimentin and cytokeratins)
together with age and metastatic status in an unselected
series of patients to determine the most significant prognos-
ticators.
Materials and methods
Clinical material
The patient groups are based on cases recorded by the
Cancer Registry of Norway in Hedmark County during the
years 1971-85. The Registry is a national register and
receives reports on all new cases of cancer in Norway based
on clinical records, pathology reports (histology, cytology,
autopsy) and death certificates. This reporting system pro-
vides multiple sets of data for each patient. Reporting is
compulsory by law, and for prostate cancer considered com-
plete.
The following variables from the database of the Cancer
Registry were included in the present study: date of diag-
nosis, age at the time of diagnosis, extension of disease
(confined to the prostate vs distant metastases) and
identification of the initial histopathological specimen. Dur-
ing the years of the present report, treatment of prostatic
carcinoma in Norway generally consisted of either surgical or
medical castration (the latter by oestrogens) or no treatment,
depending on the patient's symptoms. Radical prostatectomy
or definitive radiotherapy was not used. Transurethral or
transvesical prostatectomy was performed in cases of urethral
obstruction. Palliative radiotherapy was given for painful
metastases. Cancer treatment is not an obligatory parameter
in The Norwegian Cancer Registry, but is often recorded.
Date of death and cause of death were supplied by the
Central Bureau of Statistics, which receives all death
certificates and autopsy reports in Norway. All patients were
followed concerning survival up to December 1991. The
patients were classified as either alive, or, if dead as (1) dead
from prostate cancer or (2) dead from other causes. Deaths
from other causes were censored in the analysis.
Hedmark County has a population of 200,000 and four
hospitals. The Department of Pathology of the Norwegian
Radium Hospital provides the cyto- and histopathological
service for this county and has examined more than 95% of
the prostate cancer specimens. The overall age-adjusted
incidence rate of prostate cancer in Hedmark County is close
to the national figure in this study period (68.7 per 100,000 in
Hedmark County, compared with 65.2 per 100,000 for the
whole country). The proportion of cases histologically
examined was 79.6% in Hedmark County, whereas the
percentage for the whole country during this period was
83.0%. The distribution of prostate cancer by disease exten-
sion in the period 1971-85 in Hedmark County and in
Norway is illustrated in Table I. There was a higher propor-
tion of cases with distant metastases and regional spread in
Hedmark County.
The present study includes only patients with histologically
verified tumours prior to cancer treatment, which either were
confined to the prostate (= localised) or had distant metas-
tases verified by clinical or radiological examination. The
significance of tumour stage on survival is shown in Figure
la. The relative death hazard was 2.8 for patients with
disseminated disease compared with patients with localised
disease. After random sampling by date of birth, 163 cases of
localised cancer and 131 cases of metastatic disease were
included, excluding patients with locoregionally advanced
spread. Nine patients with previous or secondary cancer were
excluded. Finally, specimens from another 19 patients were
not found or could not be reviewed because of scanty or
insufficient material, leaving 116 patients with distant metas-
tases and 150 patients with localised disease for analysis.
Light microscopy
Only biopsies from primary tumours were selected, and when
multiple specimens were available the first specimen was
always retrieved. The tissue specimens had been fixed in 4%
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Table I Prostate cancer in Hedmark County and Norway 1971-85 by stage (%)
Localised Regional Distant Metastases Stage
tumour spread metastases not specified unknown Total
Hedmark County 62.9 5.8 24.9 1.2 5.2 100.0
Norway (total) 66.9 4.6 22.6 1.0 4.9 100.0
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Figure 1 Survival analysis of 266 cases of prostate cancer according to: a, tumour stage (localised, 150; disseminated, 116), b,
WHO grade (grade 1, 61; grade 2, 97; grade 3, 102; grade 4, 6), c, Gleason score (score 2, 5; score 3, 21; score 4, 40; score 5, 44;
score 6, 49; score 7, 39; score 8, 47; score 9, 21; score 10, 0), d, tissue prostate acid phosphatase (+ + +, 253; + +, 8; +, 2; 0, 3), e,
tissue prostate-specific antigen (+ + +, 147; + +, 65; +, 35; 0, 19). Time in months on x-axis, survival probability on y-axis.
buffered formalin and embedded in paraffin. From each
block 5 ytm sections were cut and stained with haematoxylin
and eosin for light microscopy. Histological grading accord-
ing to the Gleason (Gleason et al., 1974) and WHO (Mostofi
et al., 1980) grading systems was performed on one section
from each tumour. The WHO grades were recorded as fol-
lows: well-differentiated carcinomas = grade 1, moderately
differentiated carcinomas = grade 2, poorly differentiated car-
cinomas = grade 3 and undifferentiated carcinomas = grade
4. Cellular atypia was graded separately. All specimens were
investigated without knowledge of the clinical data by one
pathologist (A.B.). A second pathologist (J.M.N.) was con-
sulted in 25 difficult cases, and consensus was always
achieved. Ninety-one specimens were transvesical resections
(TVs), 75 were transurethral resections (TURs) and 100 were
core biopsies (CBs).
Immunohistochemistry
Paraffin-embedded material was prepared by the
avidin-biotin-peroxidase complex (ABC) method (Hsu et
al., 1981). After removal of paraffin, the sections were treated
for 30 min with 0.3% hydrogen peroxide in methanol to
block endogenous peroxidase, followed by 20 min incubation
with normal goat serum diluted 1:75 in 0.01 M phosphate-
buffered saline (pH 7.4) containing 5% bovine serum
albumin (BSA) to eliminate non-specific staining. The sec-
tions were then incubated at 4°C overnight using the antisera
listed in Table II (PAP, PSA, AEI/AE3, NSE, p53 protein,
c-erbB-2 protein, vimentin), followed by 30 min incubation
with ABC (10 g ml avidin and 2.5 tg ml-' biotin-labelled
peroxidase). The tissues were stained for 5 min with 0.05%
3'3-diaminobenzidine-tetrahydrochloride freshly prepared in
0.05% Tris buffer (pH 7.6) containing 0.01% hydrogen
peroxide and then counterstained with haematoxylin, dehyd-
rated and mounted.
Localisation of the immunostaining product in relation to
cellular morphology was noted. Only nuclear p53 staining
products and membranous c-erbB-2 staining products were
considered as positive. The fraction of immunoreactive
tumour cells was semiquantitatively graded from 0 to + + +
in each section.
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Control studies included relevant positive controls and all
showed specific immunostaining. Negative controls included
substitution of primary antiserum with relevant normal non-
specific serum diluted 1:300 or incubation with antisera
absorbed with their homologous antigens prior to testing,
and all controls were negative.
Statistics
The relationships between the different variables were
measured by the Spearman correlation coefficient statistical
package (Hintze, 1992). The death hazard was analysed by
stratified (by metastatic stage) Cox regression model
(EGRET Statistical Package, Statistics and Epidemiology
Research, Seattle, WA, USA). P-values <0.05 were regarded
as statistically significant.
Results
Distributions and comparison ofparameters
The distributions among the defined subgroups by the
Gleason and WHO grading systems are shown in Table III.
According to the WHO system, the largest subgroup was
poorly differentiated carcinoma and represented almost 40%
of all cases. The intermediate grade tumours in the Gleason
system (score 5-7) constituted 50% of all tumours. There
was a strong correlation between the WHO and the Gleason
Table II Antisera, sources and dilutions
Antiserum Dilution Source
Polyclonal PAP 1:100 a
Monoclonal PSA 1:40 Dako
AE1/AE3 1:150 ICN Immunoch.
Monoclonal NSE 1:700 Dakopatts
Polyclonal p53 protein 1:300 Novocastra
Polyclonal c-erbB-2 protein 1:40 Novocastra NCL CBII
Monoclonal vimentin 1:150 Boehringer Mannheim
Biochemicals
aA generous gift from Dr Nustad, The Norwegian Radium
Hospital.
Table III Comparison of the Gleason and the WHO system in 266
prostatic carcinomas
Gleason WHO
1 2 3 4
2 4 1 0 0
3 21 (96.7%) 0 (7.2%) 0 (0%) 0 (0%)
4 34 6 0 0
5 2 40 0 2
6 0 (3.3%) 33 (88.7%) 15 (39.2%) 1 (66.7%)
7 0 13 25 1
8 0 4 42 1
9 0 (0.0%) 0 (4.1%) 20 (60.8%) 1 (33.3%)
10 0 0 0 0
Total 61 (100.0%) 97 (100.0%) 102 (100.0%) 6 (100.0%)
system (0.85), as shown in Table IV. Discordance was noted
mainly for high-grade tumours. Four of the six WHO grade
4 tumours were grouped among the intermediate grade
tumours by the Gleason system (Gleason grade 5-7), and all
were core biopsies. We also observed significant correlations
between each of the grading systems and cellular atypia
(Table IV).
Most tumours expressed strong immunoreactivity (+ +/
+ + +) for PAP (98.1%), PSA (79.7%) and AE1/AE3
(85.0%), as shown in Table V. In well-differentiated tumours
PAP, PSA and AE1/AE3 immunoreactivity was seen in the
majority of cells (PAP, 100%; PSA, 85%; AE1/AE3, 87%).
Among intermediate-grade tumours, some were strongly
positive in most cells; others showed a focal immunoreac-
tivity. Tumours that were negative for the above-mentioned
factors were poorly differentiated (PAP, 100%; PSA, 58%;
AE1/AE3, 78%) and expressed the greatest degree of cell
heterogeneity. The three PAP-negative tumours were also
negative for PSA: two were WHO grade 3 and one WHO
grade 4. As shown in Table IV, PSA immunoreactivity cor-
related positively with PAP and AE1/AE3 immunoreactivity
(correlation coefficients 0.26 and 0.17 respectively) and
negatively with Gleason grade, WHO grade and cellular
atypia (correlation coefficients between - 0.15 and - 0.21).
PAP immunoreactivity correlated negatively with WHO
grade and positively with AE1/AE3 stainability (correlation
coefficients 0.15 and 0.17 respectively).
Only 17.3% of the tumours were p53 protein positive
(Table V). The proportion of specimens negative for NSE,
c-erbB-2 protein and vimentin was 82.0%, 98.5% and 95.1%
respectively. p53 protein immunoreactivity correlated
negatively with PAP (correlation coefficient - 0.17), while
NSE immunoreactivity correlated positively with AE1/AE3
(correlation coefficient 0.15) (Table IV).
Univariate survival analysis
Differences in survival for metastatic stage (MO vs Ml),
WHO grade, Gleason grade, tissue PAP and tissue PSA are
presented in Figure 1. The death hazard for each factor was
in accordance with the results of the univariate survival
analysis stratified for M category (Table VI).
The analysis of each factor stratified by the presence or
absence of distant metastases is shown in Table VI. The
analysis revealed that the WHO grading system, age, cellular
atypia and PAP immunoreactivity significantly predicted sur-
vival. In this analysis the Gleason system showed a poor
prognostic ability, whereas a trend towards decreased sur-
vival was observed with decreasing PSA staining and exten-
sive NSE reactivity (+ +/+ +).
Multivariate survival analysis
As shown in Table V, only four and 13 specimens were
positive for c-erbB-2 protein and vimentin respectively. Thus,
all the investigated parameters except c-erbB-2 protein and
vimentin were included in a backward stepwise Cox regres-
sion analysis stratified separately for the presence or absence
of distant metastases at time of diagnosis (Table VII). The
WHO grading system was the most powerful prognosticator
and added significant prognostic information to that
Table IV Spearman correlation coefficients between the investigated parameters in 266 specimens of prostatic
carcinomas. Significant values are given in bold type
WHO Atypia Vimentin AEJ/AE3 NSE c-erbB-2 p53 PAP PSA
Gleason 0.85 0.83 -0.03 -0.15 -0.04 -0.07 -0.03 -0.05 -0.15
WHO 0.85 -0.03 -0.08 0.10 -0.11 0.00 -0.15 -0.21
Atypia -0.01 -0.09 0.05 -0.13 -0.03 -0.08 -0.18
Vimentin 0.07 -0.01 -0.03 0.03 0.05 0.01
AE1/AE3 0.15 -0.01 -0.06 0.17 0.17
NSE -0.06 0.05 -0.07 0.04
c-erbB-2 -0.06 0.03 0.06
p53 -0.17 -0.06
PAP 0.26PROGNOSTICATORS IN PROSTATE CARCINOMA 927
Table V Expression of PAP, PSA, cytokeratins (AE1/AE3), p53
protein, NSE, c-erbB-2 protein and vimentin in 266 prostatic
carcinomas
Immunoreactivity
Antiserum 0 + ++ + + +
PAP 3 2 8 253
PSA 19 35 65 147
AEI/AE3 9 31 64 162
p53 220 30 6 10
NSE 218 30 17 1
c-erbB-2 262 3 1 0
Vimentin 253 12 1 0
Table VI Univariate survival analysis stratified by M category
(localised or metastatic stage). The analysis included age, Gleason
grade, WHO grade, cellular atypia, AE1/AE3, PSA, PAP, NSE, p53
protein, c-erbB-2 protein and vimentin. The 95% confidence limits
are given in brackets
Variable Hazard ratio
Age (years)
<59
60-69
70-79
>80
1.00 (reference)
0.92
1.23
2.21
(0.47, 1.82)
(0.65, 2.33)
(1.10, 4.44)
Likelihood ratio statistics on 3 d.f. = 13.697, P = 0.003
obtained from the metastatic stage. The other significant
factors included in this analysis were NSE (+ + +), age
(>80 years) and PAP (+++).
Discussion
A major advantage of the present study is its large number of
patients selected randomly from the entire population of
Hedmark County. A detailed T and N classification accord-
ing to the UICC classification system (Hermanek & Sobin,
1987) was not possible because this information was not
recorded in the majority of the clinical reports. The distribu-
tion by metastatic status was almost the same as for the total
population of Norway.
There has been a complete follow-up of all patients with
respect to mortality and cause ofdeath. Although the general
validity of death certificates may be discussed, the number of
errors are known to be low for malignant tumours (Glattre &
Blix, 1980). Cancer treatment is often recorded in The
Norwegian Cancer Registry but is not an obligatory
parameter.
The statistical analyses compare the relative ability of each
variable to reflect survival, regardless of treatment. The study
did not aim to predict length of survival, only the relative
death hazard of each of the investigated parameters, and we
suppose that treatment options have no selective influence on
the investigated variables in this respect. Furthermore, from
the literature there is little evidence that any of the given
therapies (surgical or medical castration) has any major
impact on survival.
For prostate cancer the most important prognostic
parameter is the presence or absence of metastases. In this
study we selected only tumours which were either confined to
the prostate (MO) or had distant metastases (Ml). The N
category remained unknown in the majority of our patients
as pelvic lymphadenectomy was not performed routinely in
patients with clinically localised disease.
The demonstration of distant metastases varied during the
15 years of the study. The majority of patients had a skeletal
radiograph taken. Bone scanning was performed routinely
only in the second half of the study period. Elevated serum
PAP alone was usually not recorded as an expression of
distant metastases. The various parameters were analysed
separately in the Cox regression model, which was stratified
by metastatic stage (MO/Mi). As shown in Table III, some
factors were either positive (PAP, AE1/AE3) or negative
(c-erbB-2, vimentin) in most tumours. This implies that such
factors, although resulting in statistically significant correla-
tions, may be of less importance for the majority of patients
because of their poor discriminating power.
Tumour grading is an attempt to predict the behaviour of
tumours on the basis of their morphology. More than 30
different grading systems have been introduced, and the
Gleason and the WHO system (identical to the Mostofi
system) are mostly used. Although many authors present
favourable results using the Gleason system, which
emphasises the two most dominant growth patterns recog-
nised at low magnification (Humphrey et al., 1991; Partin et
al., 1992; Epstein et al., 1993), others do not (Blute et al.,
1989; Gallee et al., 1990). Most grading systems also consider
Gleason
2 grade
3
4
5
6
7
8
9
1.00 (reference)
3.26
2.68
5.33
4.62
4.85
5.13
3.93
(0.42, 25.38)
(0.35, 20.24)
(0.72, 39.14)
(0.63, 33.87)
(0.66, 35.90)
(0.70, 37.68)
(0.52, 29.88)
Likelihood ratio statistics on 7 d.f. = 11.406, P = 0.122
WHO grade
1
2
3
4
1.00 (reference)
1.86
2.20
9.19
(1.14, 3.04)
(1.34, 3.62)
(3.62, 23.32)
Likelihood ratio statistics on 3 d.f. = 20.113, P = <0.001
Mild atypia
Moderate atypia
Severe atypia
1.00 (reference)
1.70
2.07
(1.10, 2.62)
(1.30, 3.30)
Likelihood ratio statistics on 2 d.f. = 10.063, P = 0.007
AEI/AE3
0
1
2
3
1.00 (reference)
0.74
1.04
1.08
(0.33, 1.67)
(0.48, 2.28)
(0.52, 2.25)
Likelihood ratio statistics on 3 d.f. = 2.701, P = 0.440
NSE
0
2
3
1.00 (reference)
0.67
1.24
21.66
(0.39, 1.14)
(0.71, 2.16)
(2.53, 185.6)
Likelihood ratio statistics on 3 d.f. = 7.366, P = 0.061
p53
0
°1
2
3
1.00 (reference)
1.14
1.17
1.92
(0.72, 1.81)
(0.43, 3.19)
(0.89, 4.15)
Likelihood ratio statistics on 3 d.f. = 2.550, P = 0.466
PAP
0
2
3
1.00 (reference)
0.96
0.14
0.12
(0.13, 7.07)
(0.003, 0.72)
(0.003, 0.51)
Likelihood ratio statistics on 3 d.f. = 9.622, P = 0.022
PSA
0
1
2
3
1.00 (reference)
0.87
0.90
0.61
(0.47, 1.61)
(0.50, 1.60)
(0.35, 1.05)
Likelihood ratio statistics on 3 d.f. = 6.682, P = 0.083
nuclear morphology. The WHO system takes into account
nuclear pleomorphism and pattern of glandular
differentiation. In an extensive multivariate survival analysis
of 12 histological and cytological factors (Schroeder et al.,928 A. BERNER et al.
Table VII Multivariate stepwise Cox regression analysis stratified
by M category (localised or metastatic stage) and resultant model.
The 95% confidence limits are given in brackets
Variable Hazard ratio
WHO
I 1.00 (reference)
2 1.94 (1.17, 3.19)
3 2.13 (1.29, 3.52)
4 7.43 (2.59, 21,31)
NSE
0 1.00 (reference)
1 0.71 (0.41, 1.22)
2 1.07 (0.61, 1.90)
3 28.93 (3.09, 271.3)
Age (years)
<59 1.00 (reference)
60-69 1.00 (0.50, 2.04)
70-79 1.28 (0.65, 2.51)
>80- 2.36 (1.14, 4.87)
PAP
0 1.00 (reference)
1 0.31 (0.04, 2.72)
2 0.17 (0.03, 0.89)
3 0.14 (0.03, 0.59)
1985), only glandular formation, nuclear anaplasia and the
number of mitotic figures were significant parameters. Gallee
et al. (1990) reviewed five different grading systems (Broders,
Anderson, Gleason, Mostofi, Mostofi-Schroeder) and found
that the best prognostic information, although not statis-
tically significant, was obtained by the Mostofi-Schroeder
and the Broders systems, while the Gleason system showed
the least prognostic ability. Furthermore, Ten Kate et al.
(1986) noticed that, compared with the complicated Gleason
system, the less complicated grading systems resulted in the
highest inter-observer reproducibility. Our data from the uni-
and multivariate Cox regression model confirm that the
WHO system (Mostofi system) is superior to the Gleason
system in predicting survival, which is in agreement with
Gallee et al. (1990) and Humphrey et al. (1991).
Like Schroeder et al. (1985), our univariate analysis dem-
onstrates that cellular atypia predicts survival. Although we
found significant correlations between the Gleason and the
WHO systems and cellular atypia, the WHO system added
prognostic information beyond that provided by the Gleason
system and by cellular atypia in the stepwise Cox regression
model. However, whereas most recent reports presenting
good prognostication using the Gleason system have been
performed on prostatectomy specimens, our series is based
on pretreatment biopsies characterised by cauterisation
artefacts (TUR-P specimens) and scanty material (core biop-
sies). As in our recent study of hormone-resistant prostatic
carcinomas (Berner et al., 1993), we noticed some underg-
rading by the Gleason system in core biopsies.
Prostate acid phosphatase and PSA are produced both in
benign and in malignant prostatic tissue and are widely used
as tumour markers (Stamey et al., 1987). In contrast to
benign epithelium, most reports on prostatic cancer tissue
demonstrate heterogeneity in immunostaining of PAP and
PSA and an apparent correlation between variation in
stainability and tumour grade (Epstein & Eggleston, 1984;
Sesterhenn et al., 1985; Feiner & Gonzales, 1986), which was
also observed in our study. Like Sesterhenn et al. (1985) and
Feiner and Gonzales (1986), we noticed that more specimens
expressed reduced or no reactivity for PSA than for PAP.
However, our uni- and multivariate analysis revealed PAP
immunostaining to be a significant and independent factor in
determining survival, which is in agreement with the findings
of Sakai et al. (1991). PSA immunostaining, on the other
hand, did not reach the level of statistical significance.
Approximately 50% of prostatic cancer specimens contain
small numbers of neuroendocrine cells (di Sant'Agnese & de
Mesy Jensen, 1987; Ro et al., 1987; Cohen et al., 1991), and
it has been suggested that the demonstration of neuroendoc-
rine features is an indicator of poor prognosis. Unlike di
Sant'Agnese and de Mesy Jensen (1987) and Cohen et al.
(1991), who used a series of different neuroendocrine
markers, we applied only one monoclonal antibody raised
against NSE, which may explain the lower scoring rate in our
series (18%). Furthermore, neuroendocrine differentiation is
mostly focal (Cohen et al., 1991) and small tissue specimens
such as core biopsies may be inadequate in demonstrating
such features. Thirty-eight per cent of the specimens in our
study were core biopsies. Extensive NSE staining (+ + +)
predicted poor outcome in the multivariate analysis. How-
ever, this was largely due to one core biopsy which his-
tologically was a small-cell carcinoma. The 95% confidence
interval was wide (Table VII), and the general significance of
this result should therefore be viewed with caution. On the
other hand, it has been reported (Ro et al., 1987) that
small-cell carcinomas in the prostate frequently demonstrate
neuroendocrine features. In a study of 20 small-cell car-
cinomas of the prostate, Tetu et al. (1987) reported a median
survival of only 5 months. The patient in our study died 4
months after diagnosis of his prostate cancer.
The published data on any potential association between
age and survival of prostate cancer are conflicting, and there
is no general support in the literature for the concept that
younger patients may have particularly aggressive tumours.
Kant et al. (1992) reported a significant decrease in the
relative 5 year survival in prostate cancer patients 75 years of
age and older, and Partin et al. (1992) in a study of localised
prostate cancer found age to be a significant and independent
parameter by multivariate analysis. The findings of Kent et
al. (1992) and Partin et al. (1992) of some relation between
age and prognosis are in agreement with ours. However, this
observation must be interpreted cautiously because of possi-
ble bias due to less intensive cancer treatment in elderly
patients.
p53 mutations and p53 protein accumulation appear to be
one of the most common features in several human neo-
plasms (Levine et al., 1991; Porter et al., 1992). In contrast to
the short half-life, wild-type p53 protein present in normal
tissues and undetectable immunohistochemically, the mutant
form can be detected by immunohistochemical techniques.
The biological significance of p53 overexpression is not yet
established, but most authors agree that p53 protein expres-
sion occurs relatively late in neoplastic transformation. In
prostate cancer nuclear p53 protein accumulation has been
correlated with histological grade (Mellon et al., 1992),
tumour progression (Berner et al., 1993) and DNA ploidy
(Visakorpi et al., 1992). Van Veldhuizen et al. (1993) recently
reported a predominant cytoplasmic staining pattern in 79%
of a series of prostatic carcinomas. However, their negative
controls were insufficient and their observations thus seem
questionable. In our study only 17% of prostatic carcinomas
demonstrated nuclear p53 protein accumulation. There was
no correlation with survival or grade, although we found a
weak trend in the univariate analysis indicating lower sur-
vival by increasing p53 protein accumulation.
Cytokeratins are a complex group of polypeptides that
form cytoskeletal intermediate filaments specific for epithelial
cells. Cytokeratin expression is found in both benign and
malignant prostatic epithelium. The AEl/AE3 antibodies
used in this study recognise high and low molecular weight
cytokeratins (Woodcock-Mitchell et al., 1982). High
molecular weight cytokeratins react in basal cells and may be
a helpful criterion for the diagnosis of well-differentiated
prostatic carcinomas (Sherwood et al., 1991). Like PAP and
PSA, cytokeratins are markers for cell maturity. Like others
(Feiner & Gonzales, 1986; Berner et al., 1993) we found
reduced or absent expression of AE1/AE3 in poorly
differentiated tumours.
Vimentin is a marker of mesenchymal tissues. However,
coexpression of cytokeratin and vimentin has been found in
normal prostatic epithelium (Leong et al., 1988; Nagle et al.,
1991). Nagle et al. (1991) observed reduced vimentin stainingPROGNOSTICATORS IN PROSTATE CARCINOMA 929
in prostatic intraepithelial neoplasia and no vimentin reac-
tivity in prostatic cancer tissue, whereas Leong et al. (1988)
found positive vimentin staining in 83% of prostatic
adenocarcinomas. In our study only 5% of the carcinomas
were vimentin positive and the variable was not useful in the
prediction of survival.
Although c-erbB-2 protein reactivity has been noticed in
many different tumours, only a few studies have been per-
formed on prostatic cancer tissue (McCann et al., 1990; Ware
et al., 1991; Mellon et al., 1992). Both Ware et al. (1991) and
Mellon et al. (1992) used fresh material and found c-erbB-2
protein expression in 71% and in 21%, respectively, while
McCann et al. (1990) did not observe c-erbB-2 protein ex-
pression in formalin-fixed tissue. Ware et al. (1991) also
compared fresh and formalin-fixed tissue, and found that
formalin fixation significantly reduced the c-erbB-2 protein
immunoreactivity, which may explain the rather low c-erbB-2
protein reactivity (1.5%) in our series.
In summary, although modern immunohistochemistry cer-
tainly yields exciting insight into the development of prostate
cancer, for the routine clinician the longer established
variables such as patient's age, WHO grade, presence of
distant metastases and PAP stainability give the most impor-
tant prognostic information in the majority of patients. The
fact that WHO grading was superior to Gleason grading and
that the impact of PAP stainability exceeds that of PSA
stainability needs further investigation.
This study was supported by The Norwegian Cancer Society.
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